Overview
- Candida auris has been reported in at least 61 countries across six continents, with U.S. data citing roughly 7,000 cases in 2025 across multiple states.
- The review reports rising virulence and resistance to major antifungal classes, including documented pan‑resistant strains.
- Conventional laboratory tests frequently misidentify the yeast, delaying correct treatment and hampering infection control in healthcare settings.
- Key traits driving spread include strong skin adhesion, biofilm formation, drug‑efflux pumps and switching from yeast to filamentous growth.
- Experts call for rapid diagnostics, stronger surveillance and new therapies, noting several antifungals in trials and the 2023 U.S. approval of rezafungin.